Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track TPST with free AI briefings, catalyst countdowns, and dilution alerts.

TPST · Tempest Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$779,000 Cash on Hand
0.5mo Cash Runway
Follow TPST by email Get an email when TPST reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about TPST, unsubscribe in one click. Privacy

📣 What TPST Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Amezalpat (TPST-1120) Hepatocellular Carcinoma (HCC) Phase 3 · NCT06680258 Not yet recruiting
Anti-LILRB2 Monoclonal Antibody IO-108 Advanced Liver Cancers Phase 1/2 · NCT04524871 Active not recruiting
Imdatifan (NKT2152) Advanced Liver Cancers Phase 1/2 · NCT04524871 Active not recruiting
Muzastotug (ADG126) Advanced Liver Cancers Phase 1/2 · NCT04524871 Active not recruiting
Tobemstomig Advanced Liver Cancers Phase 1/2 · NCT04524871 Active not recruiting
Tiragolumab Advanced Liver Cancers Phase 1/2 · NCT04524871 Active not recruiting
EP2/EP4 Antagonist TPST-1495 Solid Tumor Phase 1 · NCT04344795 Completed
Part 3 TPST-1120 Hepatocellular Carcinoma Phase 1 · NCT03829436 Completed
Part 1 TPST-1120 Hepatocellular Carcinoma Phase 1 · NCT03829436 Completed

Also used in these trials (approved or third-party drugs, not TPST's own candidates): Atezolizumab, Bevacizumab, Tocilizumab, Pembrolizumab, Nivolumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

TPST holds $779,000 in cash and short-term investments (as of Jun 30, 2026) and burns about $5.2M/quarter from operations, an estimated runway of 0.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 80 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TPST files for a raise →

👥 Who Owns TPST

Insiders 13.2% Other 5%+ holders 2.5% Institutions (25 holders) 23.7% Public and other holders 60.6%
HolderTypeShares% of sharesAs of
Versant Venture Capital VI, L.P.
10% owner
Insider 2,328,585 11.65% 2024-08-08
SABBY MANAGEMENT, LLC 5%+ holder (13G) 492,223 2.46% 2025-12-31
Matthew Angel
CEO and President, Director, 10% owner · +732,585 options
Insider 231,482 1.16% 2026-03-24
Stephen R Brady
President and CEO, Director · +800,000 options
Insider 46,376 0.23% 2024-07-03
Justin Trojanowski
Corporate Controller · +78,500 options
Insider 22,168 0.11% 2024-06-28
Samuel Whiting
Chief Medical Officer · +370,000 options
Insider 9,573 0.05% 2024-07-02
John W. Frederick
Director · +25,000 options
Insider 8,000 0.04% 2026-10-13
William Drake Richey
Director · +25,000 options
Insider 2,000 0.01% 2026-06-04

Share count 19,995,358 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full TPST picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TPST and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.